| Umoja Biopharma–MPM Capital: investment, 202011 financing round Series A totalling $53m incl existing + co-lead investor MPM Capital |
2020-11-18 |
| Umoja Biopharma–Qiming: investment, 202011 financing round Series A totalling $53m incl new + co-lead investor Qiming |
2020-11-18 |
| Umoja Biopharma–SEVERAL: investment, 202011 financing round Series A $53m co-led by MPM Capital + Qiming Venture Parners USA |
2020-11-18 |
| Umoja Biopharma–Verge Scientific Communications: public relations, 202011 service existent by Verge |
2020-11-18 |
| Nereid Therapeutics–Apple Tree Partners: investment, 202011 investment commitment $50m Series A funding from ATP |
2020-11-16 |
| Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi |
2020-11-13 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital |
2020-11-12 |
| Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer |
2020-11-12 |
| Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital |
2020-11-12 |
| Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund |
2020-11-12 |
| Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures |
2020-11-12 |
| Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund |
2020-11-12 |
| Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures |
2020-11-12 |
| Stargazer Pharmaceuticals–SEVERAL: investment, 202011 financing round Series A $57m with Novo Holdings + venBio + Canaan Partners + Pontifax + FFB |
2020-11-09 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis |
2020-11-06 |
| Cytek Biosciences–SEVERAL: investment, 202011 financing round Series D $120m co-led by RA Capital + Hillhouse Capital |
2020-11-05 |
| VelosBio–Merck (US): investment, 202011– acquisition $2.75b in cash of VelosBio by Merck |
2020-11-05 |
| Sofie Biosciences–SEVERAL: investment, 202011 financing round Series C $27.4m led by Jubilant Pharma with $25m plus 3 other investors |
2020-11-04 |
| Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures |
2020-11-02 |
| Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd |
2020-11-02 |
| Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m |
2020-11-02 |
| Horizon Discovery–PerkinElmer: investment, 202011– cash tender offer £296m ($383m) representing total enterprise value of £284m ($368m) |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC |
2020-10-29 |
| Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors |
2020-10-28 |
| Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share |
2020-10-28 |
| Gracell Biotechnologies–SEVERAL: investment, 202010 financing round Series C $100m led by Wellington + OrbiMed + Morningside Ventures |
2020-10-28 |
| Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) |
2020-10-27 |
| Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool |
2020-10-27 |
| Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II |
2020-10-27 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Base Genomics–Bristows: legal services, 202010 supply Bristows LLP legal advisor to Base Genomics for acquisition by Exact Sciences |
2020-10-26 |
| Base Genomics–Exact Sciences: investment, 202010 acquisition 100% of Base Genomics Ltd for $410m in cash (net of cash + certain other adjustments) |
2020-10-26 |
| Base Genomics–William Blair: financial services, 202010 supply William Blair financial advisor to Base Genomics for acquisition by Exact Sciences |
2020-10-26 |
| Exact Sciences–K&L Gates: legal services, 202010 supply legal advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier |
2020-10-26 |
| Exact Sciences–XMS Capital: financial services, 202010 supply financial advisor to Exact Escience for acquisitions of Base Genomics + Thrive Earlier |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
| Scorpion Therapeutics–Abingworth: investment, 202010 financing round Series A totalling $108m incl co-investor Abingworth |
2020-10-26 |
| Scorpion Therapeutics–Atlas Venture: investment, 202010 financing round Series A totalling $108m incl co-lead investor Atlas Venture |
2020-10-26 |
| Scorpion Therapeutics–Omega Funds: investment, 202010 financing round Series A totalling $108m incl co-lead investor Omega Funds |
2020-10-26 |
| Scorpion Therapeutics–Partners HealthCare: investment, 202010 financing round Series A totalling $108m incl co-investor Partners Healthcare Innovation |
2020-10-26 |
| Scorpion Therapeutics–Precision Medicine Group: public relations, 202010 service existent Stern IR is investor contact |
2020-10-26 |
| Scorpion Therapeutics–SEVERAL: investment, 202010 financing round Series A $108m led by Atlas Venture + Omega Funds + Vida Ventures |
2020-10-26 |
| Scorpion Therapeutics–Ten Bridge Communications: public relations, 202010 service existent Ten Bridge is media contact |
2020-10-26 |
| Scorpion Therapeutics–Vida Ventures: investment, 202010 financing round Series A totalling $108m incl co-lead investor Vida Ventures |
2020-10-26 |
| Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones |
2020-10-26 |
| Thrive Earlier Detection–Goldman Sachs: financial services, 202010 supply GS financial advisor to TED for acquisition by Exact Sciences |
2020-10-26 |
| Thrive Earlier Detection–Goodwin Procter: legal services, 202010 supply Goodwin Procter LLP legal advisor to TED for acquisition by Exact Sciences |
2020-10-26 |
| Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva |
2020-10-20 |
| Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BIoMedPartners plus all existing investors |
2020-10-19 |
| Azitra–Bayer: investment, 202010 financing round Series B totalling $17m incl $8m from lead investor Leaps by Bayer |
2020-10-15 |
| Azitra–Bios Partners: investment, 202010 financing round Series B totalling $17m incl existing + co-investor Bios Partners |
2020-10-15 |
| Azitra–Connecticut (govt): investment, 202010 financing round Series B totalling $17m incl existing + co-investor Connecticut Innovations |
2020-10-15 |
| Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer |
2020-10-15 |
| Oribiotech–Amadeus Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Amadeus Capital Partners |
2020-10-14 |
| Oribiotech–BAM the Agency: public relations, 202010 service existent by BAM |
2020-10-14 |
| Oribiotech–Delin Ventures: investment, 202010 financing round Series A totalling $30m incl existing + co investor Delin Ventures |
2020-10-14 |
| Oribiotech–Kindred Capital: investment, 202010 financing round Series A totalling $30m incl existing + co investor Kindred Capital |
2020-10-14 |
| Oribiotech–Northpond Ventures: investment, 202010 financing round Series A totalling $30m incl new + lead investor Northpond Ventures |
2020-10-14 |
| Oribiotech–Octopus Ventures: investment, 202010 financing round Series A totalling $30m incl new + co-lead investor Octopus Ventures |
2020-10-14 |
| Oribiotech–SEVERAL: investment, 202010 financing round Series A $30m led by Northpond Ventures alongside Octopus Ventures |
2020-10-14 |
| RayzeBio–Samsara BioCapital: investment, 202010 financing round Series A totalling $45m inc co-investor Samsara BioCapital |
2020-10-14 |
| RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures |
2020-10-14 |
| RayzeBio–VenBio: investment, 202010 financing round Series A totalling $45m inc co-lead investor venBio Partners |
2020-10-14 |
| RayzeBio–Versant Ventures: investment, 202010 financing round Series A totalling $45m inc co-lead investor Versant Ventures |
2020-10-14 |
| Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds |
2020-10-13 |
| Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum |
2020-10-13 |
| Neogene Therapeutics–Twist Bioscience: cell therapy, 202010– collab strategic partnership using DNA synthesis platform to develop T cell therapies |
2020-10-13 |
| Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences |
2020-10-13 |
| Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund |
2020-10-13 |
| Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds |
2020-10-13 |
| Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor |
2020-10-13 |
| Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds |
2020-10-13 |
| Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC |
2020-10-12 |
| Kronos Bio–SEVERAL: investment, 202010 IPO $250m+$37.5m with 13.2m+2m shares common stock at $17/share at Nasdaq Global Select Market |
2020-10-08 |
| Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group |
2020-10-07 |
| Sensei Biotherapeutics–Cambrian Biopharma: investment, 202010 financing round Series A totalling $28.5m incl co-lead investor Cambrian Biopharma |
2020-10-07 |
| Sensei Biotherapeutics–Future Ventures: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Future Ventures |
2020-10-07 |
| Sensei Biotherapeutics–H&S Ventures: investment, 202010 financing round Series A totalling $28.5m incl co-lead investor H&S Ventures |
2020-10-07 |
| Sensei Biotherapeutics–Precision Medicine Group: public relations, 202010 service existent Stern IR is investor contact |
2020-10-07 |
| Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures |
2020-10-07 |
| Sensei Biotherapeutics–Yates Network: public relations, 202010 service existent The Yates Network is media contact |
2020-10-07 |
| Federation Bio–Altitude Life Science Ventures: investment, 202010 financing round Series A totalling $50m incl existing + co-investor Altitude |
2020-10-06 |
| Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital |
2020-10-06 |
| Federation Bio–Horizons Ventures: investment, 202010 financing round Series A totalling $50m incl new + lead investor Horizons Ventures |
2020-10-06 |
| Federation Bio–Rockefeller: investment, 202010 financing round Series A totalling $50m incl existing + co-investor Venrock |
2020-10-06 |
| Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude |
2020-10-06 |
| GSK–Nvidia: AI-based drug discovery, 202010– collab with GSK AI Hub incl supply DGX A100 systems + Clara Discovery s/w + use Cambridge-1 supercomputer |
2020-10-05 |
| ReadCoor–10x Genomics: investment, 202010– acquisition $350m in cash + shares of ReadCoor by 10x Genomics |
2020-10-05 |
| Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon |
2020-10-01 |
| Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures |
2020-10-01 |
| Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures |
2020-10-01 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
